Belharra and Genentech entered into a multi-year collaboration employing Belharra’s proprietary chemoproteomics platform to discover and develop small molecule medicines in multiple therapeutic areas including oncology, immuno-oncology, autoimmune, and neurodegenerative diseases. Belharra received $80 million in an upfront payment. Read press release.
News
TIMELINE SINGLE TEMPLATE